Fulcrum Therapeutics Up Nearly 59%, on Pace for Largest Percent Increase Since August 2021 -- Data Talk

Dow Jones12-09

Fulcrum Therapeutics, Inc. (FULC) is currently at $14.13, up $5.23 or 58.76%

 

--Would be highest close since April 12, 2022, when it closed at $16.39

--On pace for largest percent increase since Aug. 10, 2021, when it rose 125.33%

--Currently up three of the past four days

--Currently up two consecutive days; up 61.3% over this period

--Best two day stretch since the two days ending Aug. 11, 2021, when it rose 142.5%

--Up 29.16% month-to-date

--Up 200.64% year-to-date; on pace for best year on record (Based on available data back to July 18, 2019)

--Down 54.38% from its all-time closing high of $30.97 on Sept. 20, 2021

--Up 252.37% from 52 weeks ago (Dec. 9, 2024), when it closed at $4.01

--Would be a new 52-week closing high

--Up 462.95% from its 52-week closing low of $2.51 on April 4, 2025

--Traded as high as $14.87; highest intraday level since Jan. 13, 2023, when it hit $15.00

--Up 67.08% at today's intraday high; largest intraday percent increase since Aug. 10, 2021, when it rose as much as 165.18%

 

All data as of 11:08:20 AM ET

 

Source: Dow Jones Market Data, FactSet

 

(END) Dow Jones Newswires

December 08, 2025 11:13 ET (16:13 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment